The DOI matches its Crossref record; 174 of the 174 references it cites were found in a registry or an index.
Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials
Open accessPublished version of a preprint
Abstract
RATIONALE: Psychedelic research continues to garner significant public and scientific interest with a growing number of clinical studies examining a wide range of conditions and disorders. However, expectancy effects and effective condition masking have been raised as critical limitations to the interpretability of the research. OBJECTIVE: In this article, we review the many methodological challenges of conducting psychedelic clinical trials and provide recommendations for improving the rigor of future research. RESULTS: Although some challenges are shared with psychotherapy and pharmacology trials more broadly, psychedelic clinical trials have to contend with several unique sources of potential bias. The subjective effects of a high-dose psychedelic are often so pronounced that it is difficult to mask participants to their treatment condition; the significant hype from positive media coverage on the clinical potential of psychedelics influences participants' expectations for treatment benefit; and participant unmasking and treatment expectations can interact in such a way that makes psychedelic therapy highly susceptible to large placebo and nocebo effects. Specific recommendations to increase the success of masking procedures and reduce the influence of participant expectancies are discussed in the context of study development, participant recruitment and selection, incomplete disclosure of the study design, choice of active placebo condition, as well as the measurement of participant expectations and masking efficacy. CONCLUSION: Incorporating the recommended design elements is intended to reduce the risk of bias in psychedelic clinical trials and thereby increases the ability to discern treatment-specific effects of psychedelic therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“leading to a general call for more effective active placebo conditions and a systematic reporting of blinding efficacy [32–34].”
The cited source says what the claim attributes to it.
In the citing paper
“systematic unblinding has been raised as a major threat to the validity of extant findings from ‘double blind’ PAT trials due to high expectancy, presumably resulting in large placebo and nocebo effects in the experimental group and the control group, respectively [32–34].”
The cited source says what the claim attributes to it.
In the citing paper
“blinding efficacy (participants, therapists) and expectancy (participants) will be assessed and reported, as recommended in the literature [32–34].”
The cited source says what the claim attributes to it.
In the citing paper
“proposing an active placebo condition aimed at maintaining blinding, while systematically assessing and reporting blinding efficacy in participants and therapists.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Mithoefer, M. C., Feduccia, A. A., Jerome, L., Mithoefer, A., Wagner, M., Walsh, Z., Hamilton, S., Yazar-Klosinski, B., Emerson, A., & Doblin, R. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05249-5 · Cited by 359
RetractedThe Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,586
Dworkin, R. H., Turk, D. C., Wyrwich, K. W., Beaton, D., Cleeland, C. S., Farrar, J. T., Haythornthwaite, J. A., Jensen, M. P., Kerns, R. D., Ader, D. N., et al. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2007.09.005 · Cited by 3,471
U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, & U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health (2006) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-4-79 · Cited by 2,856
Psychosomatic medicine in Germany: more timely than ever
Zipfel, S., Herzog, W., Kruse, J., & Henningsen, P. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447701 · Cited by 2,323
Psychometric properties of the credibility/expectancy questionnaire
Devilly, G. J., & Borkovec, T. D. (2000) · Journal of Behavior Therapy and Experimental Psychiatry · doi:10.1016/s0005-7916(00)00012-4 · Cited by 2,295
A Controlled Trial of Arthroscopic Surgery for Osteoarthritis of the Knee
Moseley, J. B., O’Malley, K. J., Petersen, N. J., Menke, T. J., Brody, B. A., Kuykendall, D. H., Hollingsworth, J. C., Ashton, C. M., & Wray, N. P. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013259 · Cited by 2,262
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Alliance in individual psychotherapy
Horvath, A. O., Del Re, A. C., Flückiger, C., & Symonds, D. (2011) · Psychotherapy · doi:10.1037/a0022186 · Cited by 2,072
Research works printed but not linked: 4
- Aday JS (2021) Delineating the association between psychedelic drug use and facets of gratitude, aesthetic experience, and relationships with nature. Dissertation, Central Michigan University
- Doblin R (1991) Pahnke’s “Good Friday experiment”: a long-term follow-up and methodological critique. J Transpers Psychol 23:1–28
- Pahnke WN (1963) Drugs and mysticism: an analysis of the relationship between psychedelic drugs and the mystical consciousness: a thesis. Dissertation. Harvard University
- Puente I (2014) Holotropic breathwork can occasion mystical experiences in the context of a daylong workshop. J Transper Res 6:40–50
Cited by
Sorted by citations
Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial
Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., et al. (2023) · JAMA · doi:10.1001/jama.2023.14530 · Cited by 545
Self-citationPharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review
van Elk, M., & Yaden, D. B. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104793 · Cited by 221
Breeksema, J. J., Kuin, B. W., Kamphuis, J., van den Brink, W., Vermetten, E., & Schoevers, R. A. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221116926 · Cited by 178
Sloshower, J., Skosnik, P. D., Safi-Aghdam, H., Pathania, S., Syed, S., Pittman, B., & D’Souza, D. C. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231154852 · Cited by 165
Kumarasamy, R. V., Natarajan, P. M., Umapathy, V. R., Roy, J. R., Mironescu, M., & Palanisamy, C. P. (2024) · Frontiers in Nanotechnology · doi:10.3389/fnano.2024.1479993 · Cited by 154
History repeating: guidelines to address common problems in psychedelic science
van Elk, M., & Fried, E. I. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231198466 · Cited by 137
Expectancy in placebo-controlled trials of psychedelics: if so, so what?
Butler, M., Jelen, L., & Rucker, J. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06221-6 · Cited by 100
Randomized trial of ketamine masked by surgical anesthesia in patients with depression
Lii, T. R., Smith, A. E., Flohr, J. R., Okada, R. L., Nyongesa, C. A., Cianfichi, L. J., Hack, L. M., Schatzberg, A. F., & Heifets, B. D. (2023) · Nature Mental Health · doi:10.1038/s44220-023-00140-x · Cited by 131
Self-citationEfficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis
Metaxa, A.-M., & Clarke, M. J. (2024) · BMJ · doi:10.1136/bmj-2023-078084 · Cited by 107
Schindler, E. A. D., Sewell, R. A., Gottschalk, C. H., Luddy, C., Flynn, L. T., Zhu, Y., Lindsey, H. M., Pittman, B. P., Cozzi, N. V., & D’Souza, D. C. (2022) · Headache The Journal of Head and Face Pain · doi:10.1111/head.14420 · Cited by 85
Expectancy Effects in Psychedelic Trials
Szigeti, B., & Heifets, B. D. (2024) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2024.02.004 · Cited by 81
Self-citationPsilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy
Dodd, S., Norman, T. R., Eyre, H. A., Stahl, S. M., Phillips, A., Carvalho, A. F., & Berk, M. (2023) · CNS Spectrums · doi:10.1017/s1092852922000888 · Cited by 73
Therapeutic mechanisms of psychedelics and entactogens
Heifets, B. D., & Olson, D. E. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01666-5 · Cited by 70
Self-citationJohnston, J. N., Kadriu, B., Allen, J., Gilbert, J. R., Henter, I. D., & Zarate, C. A. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109422 · Cited by 73
Transformative experience and informed consent to psychedelic-assisted psychotherapy
Jacobs, E. (2023) · Frontiers in Psychology · doi:10.3389/fpsyg.2023.1108333 · Cited by 75
Clinically relevant acute subjective effects of psychedelics beyond mystical experience
Yaden, D. B., Goldy, S. P., Weiss, B., & Griffiths, R. R. (2024) · Nature Reviews Psychology · doi:10.1038/s44159-024-00345-6 · Cited by 67
Psychedelic Commercialization: A Wide-Spanning Overview of the Emerging Psychedelic Industry
Aday, J. S., Barnett, B. S., Grossman, D., Murnane, K. S., Nichols, C. D., & Hendricks, P. S. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0013 · Cited by 65
Self-citationNoorani, T. N., Bedi, G., & Muthukumaraswamy, S. D. (2023) · Psychological Medicine · doi:10.1017/s0033291723001289 · Cited by 64
Huneke, N. T. M., Veronesi, G. F., Garner, M. J., Baldwin, D. S., & Cortese, S. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0085 · Cited by 68
Kopra, E. I., Ferris, J., WINSTOCK, A. R., Kuypers, K. P. C., Young, A. H., & Rucker, J. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231158245 · Cited by 67
Breeksema, J. J., Niemeijer, A., Krediet, E., Karsten, T., Kamphuis, J., Vermetten, E., van den Brink, W., & Schoevers, R. (2024) · Scientific Reports · doi:10.1038/s41598-024-53188-9 · Cited by 58
Mechanisms and molecular targets surrounding the potential therapeutic effects of psychedelics
Jaster, A. M., & González‐Maeso, J. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02274-x · Cited by 56
Holze, F., Singh, N., Liechti, M. E., & D’Souza, D. C. (2024) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2024.01.007 · Cited by 62
Aday, J. S., Skiles, Z., Eaton, N., Fredenburg, L., Pleet, M. M., Mantia, J., Bradley, E., Fernandes‐Osterhold, G., & Woolley, J. D. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2022.0004 · Cited by 50
Self-citationConn, K., Milton, L. K., Huang, K., Munguba, H., Ruuska, J., Lemus, M. B., Greaves, E., Homman‐Ludiye, J., Oldfield, B. J., & Foldi, C. J. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02575-9 · Cited by 58
An international Delphi consensus for reporting of setting in psychedelic clinical trials
Pronovost-Morgan, C., Greenway, K. T., Roseman, L., Experts, T. R., Aday, J. S., Agin-Liebes, G., Ahmad, K., Aicher, H., Aixalà, M., Amar, S., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03685-9 · Cited by 54
Self-citationEmerging Challenges for Psychedelic Therapy
Aday, J. S., Carhart-Harris, R. L., & Woolley, J. D. (2023) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2023.0549 · Cited by 47
Self-citationPsychedelic-assisted psychotherapy: Where is the psychotherapy research
Aday, J. S., Horton, D., Fernandes-Osterhold, G., O’Donovan, A., Bradley, E. R., Rosen, R. C., & Woolley, J. D. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06620-x · Cited by 54
Self-citationBorkel, L. F., Rojas‐Hernández, J., Henríquez‐Hernández, L. A., Santana, Á., & Hernández, D. J. Q. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2295997 · Cited by 50
The need for establishing best practices and gold standards in psychedelic medicine
Feduccia, A. A., Agin-Liebes, G., Price, C. M., Grinsell, N., Paradise, S., & Rabin, D. M. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.03.083 · Cited by 44
Schipper, S., Nigam, K. B., Schmid, Y., Piechotta, V., Ljuslin, M., Beaussant, Y., Schwarzer, G., & Boehlke, C. S. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015383.pub2 · Cited by 44
Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression
Weiss, B., Ginige, I., Shannon, L., Giribaldi, B., Murphy-Beiner, A., Murphy, R., Baker-Jones, M., Martell, J., Nutt, D. J., Carhart-Harris, R. L., et al. (2023) · Psychological Medicine · doi:10.1017/s0033291723001514 · Cited by 48
Assessment of the Acute Effects of 2C‐B vs. Psilocybin on Subjective Experience, Mood, and Cognition
Mallaroni, P., Mason, N. L., Reckweg, J. T., Paci, R., Ritscher, S., Toennes, S. W., Theunissen, E. L., Kuypers, K. P. C., & Ramaekers, J. G. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2958 · Cited by 42
Psychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential
Allen, J., Dames, S., Foldi, C. J., & Shultz, S. R. (2024) · Molecular Psychiatry · doi:10.1038/s41380-023-02360-0 · Cited by 40
Seeking the Psilocybiome: Psychedelics meet the microbiota-gut-brain axis
Kelly, J. R., Clarke, G. A., Harkin, A., Corr, S. C., Galvin, S. D., Pradeep, V., Cryan, J. F., O’Keane, V., & Dinan, T. G. (2022) · International Journal of Clinical and Health Psychology · doi:10.1016/j.ijchp.2022.100349 · Cited by 40
Garel, N., Drury, J., Lévesque, J. T., Goyette, N., Lehmann, A., Looper, K. J., Erritzøe, D., Dames, S., Turecki, G., Rej, S., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1268832 · Cited by 39
A Systematic Review of Study Design and Placebo Controls in Psychedelic Research
Wen, A. Q., Singhal, N., Jones, B. D. M., Zeifman, R. J., Mehta, S. H., Shenasa, M. A., Blumberger, D. M., Daskalakis, Z. J., & Weissman, C. R. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0028 · Cited by 42
Psilocybin and Other Classic Psychedelics in Depression
Nutt, D., Peill, J. M., Weiss, B., Godfrey, K., Carhart-Harris, R. L., & Erritzøe, D. (2023) · Current topics in behavioral neurosciences · doi:10.1007/7854_2023_451 · Cited by 39
A Systematic Review of Participant Diversity in Psychedelic-Assisted Psychotherapy Trials
Haft, S. L., Downey, A. E., Raymond‐Flesch, M., Fernandes‐Osterhold, G., Bradley, E., O’Donovan, A., & Woolley, J. D. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2025.116359 · Cited by 38
Self-citationHietamies, T. M., McInnes, L. A., Klise, A., Worley, M. J., Qian, J. J., Williams, L. M., Heifets, B. D., & Levine, S. P. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.04.141 · Cited by 33
Self-citationBeyond the psychedelic hype: Exploring the persistence of the neoliberal paradigm
Davies, J., Pace, B. A., & Devenot, N. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2023.00273 · Cited by 33
Psychedelics in neuroinflammation: Mechanisms and therapeutic potential
de Deus, J. L., Maia, J. M., Soriano, R. N., Amorim, M. R., & Branco, L. G. S. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111278 · Cited by 35
Harnessing placebo: Lessons from psychedelic science
Pronovost-Morgan, C., Hartogsohn, I., & Ramaekers, J. G. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231182602 · Cited by 39
Weiss, B., Roseman, L., Giribaldi, B., Nutt, D., Carhart-Harris, R. L., & Erritzøe, D. (2024) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-024-01253-9 · Cited by 41
Benefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression
Ramaekers, J. G., Reckweg, J. T., & Mason, N. L. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230890 · Cited by 35
McIntyre, R. S., Kwan, A. T. H., Mansur, R. B., Oliveira-Maia, A. J., Teopiz, K. M., Maletic, V., Suppes, T. M., Stahl, S. M., & Rosenblat, J. D. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230902 · Cited by 33
Wulff, A. B., Nichols, C. D., & Thompson, S. M. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109504 · Cited by 35
Psilocybin therapy for mood dysfunction in Parkinson’s disease: an open-label pilot trial
Bradley, E., Sakai, K., Fernandes‐Osterhold, G., Szigeti, B., Ludwig, C., Ostrem, J. L., Tanner, C. M., Bock, M., Llerena, K., Finley, P. R., et al. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02097-0 · Cited by 35
Self-citationOptimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation
Modlin, N. L., Miller, T. M., Rucker, J., Kirlić, N., Lennard-Jones, M., Schlosser, D. A., & Aaronson, S. T. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.01.077 · Cited by 31
History repeating: A roadmap to address common problems in psychedelic sciencePreprint
van Elk, M., & Fried, E. I. (2023) · doi:10.31234/osf.io/ak6gx · Cited by 30
Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression
Mertens, L. J., Koslowski, M., Betzler, F., Brand, M., Evens, R., Kärtner, L., Jungaberle, A., Jungaberle, H., Majić, T., Schmitz, C. N., et al. (2026) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2026.0132 · Cited by 39
Perkins, D., Ruffell, S., Day, K., Rubiano, D. P., & Sarris, J. J. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.879221 · Cited by 33
Kiraga, M. K., Kuypers, K. P. C., Uthaug, M. V., Ramaekers, J. G., & Mason, N. L. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.883869 · Cited by 26
Addressing blinding in classic psychedelic studies with innovative active placebos
Aday, J. S., Simonsson, O., Schindler, E. A. D., & D’Souza, D. C. (2025) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaf023 · Cited by 28
Self-citationRandomized Trial of Ketamine Masked by Surgical Anesthesia in Depressed PatientsPreprint
Lii, T. R., Smith, A. E., Flohr, J. R., Okada, R. L., Nyongesa, C. A., Cianfichi, L. J., Hack, L. M., Schatzberg, A. F., & Heifets, B. D. (2023) · medRxiv · doi:10.1101/2023.04.28.23289210 · Cited by 26
Self-citationOkano, L., Jones, G., Deyo, B., Brandenburg, A., & Hale, W. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.965641 · Cited by 24
A lexicon for psychedelic research and treatment
Nutt, D. J., Erritzøe, D., Schlag, A. K., Luke, D. P., Mash, D. C., Uchida, H., Aday, J. S., Rucker, J., Galindo, L., Sweeney, M., et al. (2025) · Drug Science Policy and Law · doi:10.1177/20503245251380511 · Cited by 24
Self-citationGattuso, J. J., Wilson, C., Hannan, A. J., & Renoir, T. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.16017 · Cited by 24
Tolle, H. M., Farah, J. C., Mallaroni, P., Mason, N. L., Ramaekers, J. G., & Amico, E. (2023) · Network Neuroscience · doi:10.1162/netn_a_00349 · Cited by 21
Humphreys, K. N., Korthuis, P. T., Stjepanović, D., & Hall, W. (2024) · Annual Review of Psychology · doi:10.1146/annurev-psych-020124-023532 · Cited by 26
Dworkin, R. H., Anderson, B. T., Andrews, N., Edwards, R. R., Grob, C. S., Ross, S., Satterthwaite, T. D., & Strain, E. C. (2022) · Journal of Pain · doi:10.1016/j.jpain.2022.05.003 · Cited by 22
The illusion of knowledge in the emerging field of psychedelic research
Oña, G., Kohek, M., & Bouso, J. C. (2022) · New Ideas in Psychology · doi:10.1016/j.newideapsych.2022.100967 · Cited by 24
Aday, J. S., McAfee, J., Conroy, D. A., Hosanagar, A., Tarnal, V., Weston, C. L., Scott, K., Horowitz, D., Geller, J. A., Harte, S. E., et al. (2025) · Frontiers in Pain Research · doi:10.3389/fpain.2025.1527783 · Cited by 22
Self-citationThe science of psychedelic medicine
Siegel, J. S., Liston, C. M., Nicol, G. E., Carhart-Harris, R. L., & Bogenschutz, M. P. (2026) · Nature Medicine · doi:10.1038/s41591-025-04194-5 · Cited by 27
Nadeem, Z., Parker, S., McGovern, H. T., & Oestreich, L. (2024) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674241261779 · Cited by 23
Psilocybin increases optimistic engagement over time: computational modelling of behaviour in rats
Fisher, E. L., Smith, R. S., Conn, K., Corcoran, A. W., Milton, L. K., Hohwy, J., & Foldi, C. J. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03103-7 · Cited by 23
Świeczkowski, D., Kwaśny, A., Pruc, M., Gaca, Z., Szarpak, P. L., & Cubała, W. J. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.116337 · Cited by 21
Modifying Informed Consent to Help Address Functional Unmasking in Psychedelic Clinical Trials
Matvey, M., Kelley, D. P., Bradley, E., Chiong, W., O’Donovan, A., & Woolley, J. D. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2024.4312 · Cited by 20
Self-citationPsychedelic medicines for end-of-life care: Pipeline clinical trial review 2022
Jing, X., Hoeh, N. R., & Menkes, D. B. (2023) · Palliative & Supportive Care · doi:10.1017/s147895152300069x · Cited by 17
Matsingos, A., Wilhelm, M., Noor, L., Yildiz, C., Rief, W., Hofmann, S. G., Falkenberg, I., & Kircher, T. T. J. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1346697 · Cited by 20
Basedow, L. A., Majić, T., Hafiz, N. J., Algharably, E. A. E., Kreutz, R. H., & Riemer, T. (2024) · Scientific Reports · doi:10.1038/s41598-024-65391-9 · Cited by 19
Inserra, A., Piot, A., Gregorio, D. D., & Gobbi, G. (2023) · CNS Drugs · doi:10.1007/s40263-023-01008-5 · Cited by 19
Glynos, N. G., Aday, J. S., Kruger, D. J., Boehnke, K. F., Lake, S., & Lucas, P. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1349565 · Cited by 17
Self-citationGomez-Escolar, A., Folch‐Sanchez, D., Stefaniuk, J., Swithenbank, Z., Nisa, A., Braddick, F., Chaudhary, N. I., van der Meer, P. B., & Batalla, A. (2024) · CNS Drugs · doi:10.1007/s40263-024-01101-3 · Cited by 21
Effects of Ayahuasca on Gratitude and Relationships with Nature: A Prospective, Naturalistic Study
Aday, J. S., Bloesch, E. K., Davis, A. K., Domoff, S. E., Scherr, K. C., Woolley, J. D., & Davoli, C. C. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2312980 · Cited by 18
Self-citationWeiss, B., Sleep, C., Miller, J. D., & Campbell, W. K. (2023) · Journal of Personality Disorders · doi:10.1521/pedi.2023.37.2.131 · Cited by 15
What is Psychological Support in the Context of Psychedelic Clinical Trials?
Richard, J., & Levine, M. A. (2025) · Psychedelic Medicine · doi:10.1089/psymed.2024.0026 · Cited by 14
Berkovitch, L., Fauvel, B., Preller, K. H., & Gaillard, R. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106239 · Cited by 16
Psychedelic-assisted therapy as a complex intervention: implications for clinical trial design
Muthukumaraswamy, S. D., Baggott, M. J., Schenberg, E. E., Repantis, D., Wolff, M., Forsyth, A., & Noorani, T. N. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251381074 · Cited by 16
Blinding Integrity in Psychedelic Randomized Clinical Trials
Orsini, D. K., Wong, S., Luch, S. D. D., Chan, B., Vasudeva, S., Lovell, G. F. M., Le, G. H., Jones, B. D. M., Chisamore, N., Mollica, A., et al. (2026) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2026.0255 · Cited by 19
Muthukumaraswamy, S. D. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2279736 · Cited by 16
Weiss, B., Sleep, C. E., Beller, N. M., Erritzøe, D., & Campbell, W. K. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2023.00291 · Cited by 15
Psilocybin for Depression: From Credibility to Feasibility, What’s Missing?
Munafò, A., Arillotta, D., Mannaioni, G., Schifano, F., Bernardini, R., & Cantarella, G. (2022) · Pharmaceuticals · doi:10.3390/ph16010068 · Cited by 15
Psychedelic-assisted therapy among sexual and gender minority communities
Hanshaw, B. D., Fusunyan, M. A., Anderson, C. T. M., & Turban, J. L. (2024) · Nature Mental Health · doi:10.1038/s44220-024-00252-y · Cited by 15
Schenberg, E. E. (2025) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70097 · Cited by 14
Vanderijst, L., Hever, F., Buot, A., Dauré, C., Benoit, J., Hanak, C., Veeser, J., Morgiève, M., Campanella, S., Kornreich, C., et al. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-05502-y · Cited by 13
Atiq, M. A., Baker, M. R., Voort, J. L. V., Vargas, M. V., & Choi, D. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06599-5 · Cited by 16
Nicholas, C. R. N., Banks, M. I., Lennertz, R. C., Wenthur, C. J., Krause, B. M., Riedner, B. A., Smith, R., Hutson, P. R., Sauder, C. J., Dunne, J. D., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03059-8 · Cited by 13
Rucker, J., Butler, M., Hambleton, S., Bird, C., Seynaeve, M., Cheema, S., Campbell‐Coker, K., Maggio, C., Dunbar, F., Lambru, G., et al. (2024) · Headache The Journal of Head and Face Pain · doi:10.1111/head.14837 · Cited by 13
History, Hype, and Responsible Psychedelic Medicine: A Qualitative Study of Psychedelic Researchers
Barber, M., Gardner, J., & Carter, A. (2024) · Journal of Bioethical Inquiry · doi:10.1007/s11673-024-10386-4 · Cited by 13
How to Make Psychedelic-Assisted Therapy Safer
Villiger, D. (2024) · Cambridge Quarterly of Healthcare Ethics · doi:10.1017/s0963180124000604 · Cited by 13
Kuburi, S., Passa, A.-M. D., Tassone, V. K., Mahmood, R., Lalovic, A., Ladha, K. S., Dunlop, K., Rizvi, S. J., Demchenko, I., & Bhat, V. (2022) · Chronic Stress · doi:10.1177/24705470221115342 · Cited by 14
Ethical considerations in rapid and novel treatments in psychiatry
Haeusermann, T., & Chiong, W. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01635-y · Cited by 13
Sakai, K., Bradley, E., Zamaria, J. A., Agin-Liebes, G., Kelley, D. P., Fish, A., Martini, V., Ferris, M. C., Morton, E. E., Michalak, E. E., et al. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06585-x · Cited by 15
Self-citationThe therapeutic potential of psychedelics
Schindler, E. A. D., & D’Souza, D. C. (2022) · Science · doi:10.1126/science.abn5486 · Cited by 12
Expectancy Effects Cannot Be Neglected in MDMA-Assisted Therapy Research
Flameling, L. J., Aday, J. S., & van Elk, M. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00692 · Cited by 12
Self-citationAssessing potential of psilocybin for depressive disorders
Kozak, Z., Johnson, M. W., & Aaronson, S. T. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2273493 · Cited by 11
Mathai, D. S., Hilbert, S. N., Sepeda, N. D., Strickland, J. C., Griffiths, R. R., & Garcia‐Romeu, A. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0035 · Cited by 11
Evaluating the potential for psilocybin as a treatment for post-traumatic stress disorder
Miller, C., & Zoladz, P. R. (2024) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.124.002237 · Cited by 13
Sutherland, I., Ho, M., & Croarkin, P. E. (2025) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2024.0082 · Cited by 11
Metadata
- Authors
- Aday, J. S., Heifets, B. D., Pratscher, S. D., Bradley, E., Rosen, R., & Woolley, J. D.
- Affiliations
- San Francisco VA Medical Center (US)
- Stanford Medicine (US)
- University of Florida Health (US)
- Corresponding author
- Aday, Jacob S.
- Heifets, Boris D.
- Pratscher, Steven D.
- Bradley, Ellen
- Rosen, Raymond
- Woolley, Joshua D.
- Venue
- Psychopharmacology
- Published
- 2022-04-01
- Volume
- 239
- Issue
- 6
- Pages
- 1989-2010
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- PMC
- PMC10184717
- OpenAlex
- W4226207502
- Cited by
- 237
- References
- 174
- Citations by year
- 2026: 49 · 2025: 59 · 2024: 64 · 2023: 47 · 2022: 18
- FWCI
- 7.84
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- public-domain
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- PsyArXiv (OSF Preprints) (submittedVersion)
- PsyArXiv (OSF Preprints) (submittedVersion, public-domain)
- Funders
- U.S. Department of Veterans Affairs (IK4 CX002090)
- University of California, San Francisco
- National Institute on Aging (T32AG049673)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Keywords
- placebo effect, nocebo effect, expectancy effects, active placebo, treatment expectations, bias mitigation, research design, participant recruitment
- MeSH terms
- Hallucinogens, Humans, Motivation, Psychotherapy, Research Design
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
